APS FORUM 2018

8.45-9.15 KEY NOTE LECTURE:
Focus on new tests and techniques by Katrien Devreese (Belgium)

9.15-9.30
Savino Sciascia (Italy): Risk stratification and scoring system models in APS

9.30-10.00
Current criteria: The need for standardization of assays and reliability of aPL results

9.30-9.45
Maria Efthymiou (United Kingdom): LAC results APS ACTION

9.45-10.00
Savino Sciascia (Italy): aPL results APS ACTION

10.00-10.15
Walid Chayouâ (the Netherlands): Is there an added value of IgM: results from a multicenter study

10.15-10.30
Rolf Urbanus (the Netherlands): Unraveling the lupus anticoagulant paradox: evidence for an important role for FV

11.00-11.15
Pieter De Kesel (Belgium): Does DOAC-Stop® eliminate the effect of DOAC on lupus anticoagulant testing?

11.15-11.30
Pieter De Kesel (Belgium): Evaluation of the effect of unfractionated heparin, enoxaparin and danaparoid on lupus anticoagulant testing

11.30-11.45
Oscar Cabrera-Marante (Spain): Incidence of thromboembolic events in asymptomatic carriers of IgA anti-b2glycoprotein-I antibodies: a 5 year follow-up

11.45-12.00
Manuel Serrano (Spain): Anti-b2glycoprotein I antibodies of the IgA isotype recognize epitopes in domain 3, 4 and 5 that are located in the same lateral zone of the molecule

12.00-12.15
Marta Tonello (Italy): IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers

12.15-12.30
Antonio Serrano (Spain): The determination of non-criteria antiphospholipid antibodies makes it possible to relate APS to over one third of patients with ischemic stroke

12.30-12.45
Jose Omar Latino (Argentina): What is the best time to assess the antiphospholipid antibodies profile to better predict the obstetric outcome in antiphospholipid syndrome patients?

14.00-14.30 KEY NOTE LECTURE:
Antiphospholipid Syndrome: It’s Far More Than You Think by Richard Furie (USA)

14.30-14.50
Ricard Cervera (Spain): Pitfalls in the organization of an APS multicenter study

14.50-15.05
Hannah Cohen (United Kingdom): Update on the RISAPS study (Rivaroxaban for Stroke Patients with APS)

15.05-15.20
Stéphane Zuily (France): Proposal for the creation of a European registry on DOACs use in APS

15.20-15.45
Angela Tincani (Italy): The possible role of APL European Forum in the ERN network: towards a European APS registry

15.45-16.00
Arsene Mekinian (France): A multicenter study to determine obstetrical outcome and treatments during pregnancy in seronegative primary APS

16.00-16.10
Cristina Belizna (France): First results on the retrospective part of the Hibiscus Study

16.40-16.55
Massimo Radin (Italy): Withdrawing anticoagulation when antiphospholipid antibodies turn negative: the role of the laboratory

16.55-17.10
Savino Sciascia (Italy): Therapeutic options when antiphospholipid antibodies turn negative

17.10-17.25
Virginie Dufrost (France): Use of direct oral anticoagulant in antiphospholipid syndrome: systematic review of literature

17.25-17.40
Manuel Serrano (Spain): Immune complexes of b2glycoprotein I in patients with IgA antiphospholipid antibodies identify patients with elevated risk of early mortality after heart transplantation

17.40-17.50
Nathalie Noirclerc (France): Heart valve disease in antiphospholipid syndrome: clinical and laboratory associations and risk factors for disease progression

8.00-8.10
Carlos Ramirez (USA): Evaluation of a novel multi-analyte assay for the detection of autoantibodies in the diagnosis of antiphospholipid syndrome

8.10-8.20
Irene Cecchi (Italy): A validation study of the global antiphospholipid syndrome score (GAPSS) in women with systemic lupus erythematosus and pregnancy morbidity

8.20-8.30
Daniel E. Pleguezuelo (Spain): Anti-phosphatidyl-serine/prothrombin IgG and IgM antibodies in unexplained obstetric morbidity

8.30-8.40
Ljudmila Stojanovich (Serbia): Presence of immune complexes of IgG/IgM bound to b2glycopotein I is associated with non-criteria manifestations in antiphospholipid syndrome

8.40-8.50
Enrico Fuzzi (Sweden): Antiphospholipid antibodies in SLE define a subset of patients with hematological abnormalities and greater damage accrual

8.50-9.00
Tatiana Lisitsyna (Russia): Mental disorders in secondary antiphospholipid syndrome patients

9.00-9.10
Irene Cecchi (Italy): Is it time for biologic therapy in antiphospholipid syndrome?

9.15-9.45 KEY NOTE LECTURE:
Updating of APS pathophysiology: does it impact on our clinical management? by Pier-Luigi Meroni (Italy)

9.45-10.10
Karl Lackner (Germany): Antiphospholipid antibody-induced cellular responses depend on epitope specificity

10.10-10.25
Stéphane Zuily (France): Is APS a thrombophilia or vasculopathy?

10.25-10.40
Vittorio Pengo (Italy): The role of platelets and thrombocytopenia in APS

10.40-10.55
Elisabet Svenungsson (Sweden): Microparticles in APS

11.25-11.45 KEY NOTE LECTURE:
Lipids in APS by Coen Hemker (the Netherlands)

11.45-12.00
Claudia Grossi (Italy): New insight into antiphospholipid syndrome: antibodies to b2glycoprotein I-domain V fail to induce thrombi in rats

12.00-12.15
Paola Adele Lonati (Italy): Complement activation in APS: evaluation of platelet-bound C4d in ex-vivo and in-vitro studies

12.15-12.30
Natalie Sippl (Sweden): Characterization of b2-glycoprotein I specific B cells from patients with the antiphospholipid syndrome

12.30-12.45
Thomas Moulinet (France): Predictive value of thrombocytopenia in antiphospholipid syndrome